Felix Hernandez

List of Publications by Year
in descending order

187 papers	11,064 citations	31974 53 h-index	32838 100 g-index
189 all docs	189 docs citations	189 times ranked	12005 citing authors

#	Article	IF	Citations
1	Role of Tau Protein in Both Physiological and Pathological Conditions. Physiological Reviews, 2004, 84, 361-384.	28.8	787
2	Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO Journal, 2001, 20, 27-39.	7.8	783
3	Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418. Journal of Biological Chemistry, 2003, 278, 45937-45945.	3.4	451
4	GSK-3ÃŽÂ², a pivotal kinase in Alzheimer disease. Frontiers in Molecular Neuroscience, 2014, 7, 46.	2.9	383
5	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3Î² in the brain but do not form tau filaments. Journal of Neurochemistry, 2002, 83, 1529-1533.	3.9	323
6	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. European Journal of Neuroscience, 2007, 25, 81-86.	2.6	300
7	Tauopathies. Cellular and Molecular Life Sciences, 2007, 64, 2219-2233.	5.4	253
8	GSK3: A possible link between beta amyloid peptide and tau protein. Experimental Neurology, 2010, 223, 322-325.	4.1	240
9	GSK3 and Tau: Two Convergence Points in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S141-S144.	2.6	238
10	Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3. Journal of Neuroscience, 2006, 26, 5083-5090.	3.6	234
11	Neuronal Induction of the Immunoproteasome in Huntington's Disease. Journal of Neuroscience, 2003, 23, 11653-11661.	3.6	228
12	Extracellular tau is toxic to neuronal cells. FEBS Letters, 2006, 580, 4842-4850.	2.8	208
13	FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain. Molecular and Cellular Neurosciences, 2001, 18, 702-714.	2.2	207
14	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456.	4.8	201
15	Distinct Priming Kinases Contribute to Differential Regulation of Collapsin Response Mediator Proteins by Glycogen Synthase Kinase-3 in Vivo. Journal of Biological Chemistry, 2006, 281, 16591-16598.	3.4	198
16	Chronic lithium administration to FTDPâ€17 tau and GSKâ€3Î² overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but preâ€formed neurofibrillary tangles do not revert. Journal of Neurochemistry, 2006, 99, 1445-1455.	3.9	197
17	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nature Medicine, 2014, 20, 881-885.	30.7	183
18	Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. Journal of Alzheimer's Disease, 2003, 5, 301-308.	2.6	172

#	Article	IF	Citations
19	Direct Evidence of Internalization of Tau byÂMicroglia In Vitro and InÂVivo. Journal of Alzheimer's Disease, 2016, 50, 77-87.	2.6	165
20	Proteasomal-Dependent Aggregate Reversal and Absence of Cell Death in a Conditional Mouse Model of Huntington's Disease. Journal of Neuroscience, 2001, 21, 8772-8781.	3.6	153
21	Absence of CX3CR1 impairs the internalization of Tau by microglia. Molecular Neurodegeneration, 2017, 12, 59.	10.8	144
22	Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35. Journal of Biological Chemistry, 2004, 279, 3801-3806.	3.4	122
23	Role of Neuroinflammation in Adult Neurogenesis and Alzheimer Disease: Therapeutic Approaches. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	121
24	N-terminal Cleavage of GSK-3 by Calpain. Journal of Biological Chemistry, 2007, 282, 22406-22413.	3.4	120
25	GSK-3Î² overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Molecular Psychiatry, 2013, 18, 451-460.	7.9	117
26	Role of glycogen synthase kinase-3 in Alzheimerâ€™s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Review of Neurotherapeutics, 2010, 10, 703-710.	2.8	111
27	Î±-Helix Structure in Alzheimer's Disease Aggregates of Tau-Proteinâ€. Biochemistry, 2002, 41, 7150-7155.	2.5	110
28	Cooexpression of FTDP-17 tau and GSK-3Î² in transgenic mice induce tau polymerization and neurodegeneration. Neurobiology of Aging, 2006, 27, 1258-1268.	3.1	105
29	Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiology of Disease, 2010, 37, 622-629.	4.4	100
30	Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. FEBS Journal, 2002, 269, 1484-1489.	0.2	92
31	Extracellular Monomeric Tau Is Internalized by Astrocytes. Frontiers in Neuroscience, 2019, 13, 442.	2.8	91
32	Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. Journal of Neurochemistry, 2006, 98, 1585-1596.	3.9	89
33	Tau Phosphorylation by GSK3 in Different Conditions. International Journal of Alzheimer's Disease, 2012, 2012, 1-7.	2.0	89
34	Tau Structures. Frontiers in Aging Neuroscience, 2016, 8, 262.	3.4	86
35	Acute Polyglutamine Expression in Inducible Mouse Model Unravels Ubiquitin/Proteasome System Impairment and Permanent Recovery Attributable to Aggregate Formation. Journal of Neuroscience, 2010, 30, 3675-3688.	3.6	82
36	Propagation of Tau via Extracellular Vesicles. Frontiers in Neuroscience, 2019, 13, 698.	2.8	78

#	Article	IF	Citations
37	The role of glycogen synthase kinase 3 in the early stages of Alzheimersâ€™ disease. FEBS Letters, 2008, 582, 3848-3854.	2.8	77
38	GSK-3 inhibitors for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2007, 7, 1527-1533.	2.8	76
39	Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Molecular and Cellular Biochemistry, 2010, 344, 211-215.	3.1	74
40	Tau Overexpression Results in Its Secretion via Membrane Vesicles. Neurodegenerative Diseases, 2012, 10, 73-75.	1.4	74
41	Novel function of Tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. EMBO Journal, 2016, 35, 1417-1436.	7.8	74
42	Selective alterations of neurons and circuits related to early memory loss in AlzheimerÃ¢â,¬â„¢s disease. Frontiers in Neuroanatomy, 2014, 8, 38.	1.7	72
43	M1 muscarinic receptor activation protects neurons from Î²-amyloid toxicity. A role for Wnt signaling pathway. Neurobiology of Disease, 2004, 17, 337-348.	4.4	71
44	Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Molecular Neurodegeneration, 2007, 2, 17.	10.8	71
45	GSK3Î² overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus, 2011, 21, 910-922.	1.9	71
46	New Features about Tau Function and Dysfunction. Biomolecules, 2016, 6, 21.	4.0	67
47	Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neuroscience Letters, 2004, 357, 143-146.	2.1	64
48	The role of GSK3 in Alzheimer disease. Brain Research Bulletin, 2009, 80, 248-250.	3.0	64
49	GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. Frontiers in Molecular Neuroscience, 2011, 4, 45.	2.9	64
50	Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 15437.	3.3	63
51	Tau Protein and Adult Hippocampal Neurogenesis. Frontiers in Neuroscience, 2012, 6, 104.	2.8	62
52	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO Journal, 2007, 26, 2743-2754.	7.8	59
53	Novel connection between newborn granule neurons and the hippocampal CA2 field. Experimental Neurology, 2015, 263, 285-292.	4.1	59
54	InÂVivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. Stem Cell Reports, 2020, 15, 1056-1066.	4.8	56

#	Article	IF	Citations
55	Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-Î²-peptide aggregation. Neuroscience Letters, 2007, 429, 91-94.	2.1	55
56	Biochemical, Ultrastructural, and Reversibility Studies on Huntingtin Filaments Isolated from Mouse and Human Brain. Journal of Neuroscience, 2004, 24, 9361-9371.	3.6	52
57	Peripherally triggered and GSK-3Î²-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. Translational Psychiatry, 2014, 4, e463-e463.	4.8	52
58	Quinones Facilitate the Self-Assembly of the Phosphorylated Tubulin Binding Region of Tau into Fibrillar Polymers. Biochemistry, 2004, 43, 2888-2897.	2.5	51
59	The Ubiquitin-Proteasome System in Huntingtonâ€™s Disease. Neuroscientist, 2005, 11, 583-594.	3.5	50
60	Tau Phosphorylation, Aggregation, and Cell Toxicity. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-5.	3.0	50
61	Dual effects of increased glycogen synthase kinase-3Î² activity on adult neurogenesis. Human Molecular Genetics, 2013, 22, 1300-1315.	2.9	49
62	Tau in neurodegenerative diseases: Tau phosphorylation and assembly. Neurotoxicity Research, 2004, 6, 477-482.	2.7	47
63	GSK3 Inhibitors and Disease. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1024-1029.	2.4	46
64	Function of tau protein in adult newborn neurons. FEBS Letters, 2009, 583, 3063-3068.	2.8	46
65	Lithium, a Potential Protective Drug in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2008, 5, 247-249.	1.4	44
66	Lithium as a Treatment for Alzheimerâ€™s Disease: The Systems Pharmacology Perspective. Journal of Alzheimer's Disease, 2019, 69, 615-629.	2.6	44
67	Cognitive Decline in Neuronal Aging and Alzheimer's Disease: Role of NMDA Receptors and Associated Proteins. Frontiers in Neuroscience, 2017, 11, 626.	2.8	43
68	Characteristics of the binding of thioflavin S to tau paired helical filaments. Journal of Alzheimer's Disease, 2006, 9, 279-285.	2.6	42
69	Tau Aggregates and Tau Pathology. Journal of Alzheimer's Disease, 2008, 14, 449-452.	2.6	42
70	Enhaced induction of the immunoproteasome by interferon gamma in neurons expressing mutant huntingtin. Neurotoxicity Research, 2004, 6, 463-468.	2.7	41
71	GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiology of Aging, 2003, 24, 1087-1094.	3.1	40
72	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 472-480.	3.8	38

#	Article	IF	Citations
73	Differences Between Human and Murine Tau at the N-terminal End. Frontiers in Aging Neuroscience, 2020, 12, 11.	3.4	38
74	Testing the ubiquitinâ€“proteasome hypothesis of neurodegeneration in vivo. Trends in Neurosciences, 2004, 27, 66-69.	8.6	36
75	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. International Journal of Molecular Sciences, 2018, 19, 645.	4.1	36
76	Tau Isoform with Three Microtubule Binding Domains is a Marker of New Axons Generated from the Subgranular Zone in the Hippocampal Dentate Gyrus: Implications for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 921-930.	2.6	35
77	Thermodynamics of the Interaction between Alzheimer's Disease Related Tau Protein and DNA. PLoS ONE, 2014, 9, e104690.	2.5	34
78	Different Susceptibility to Neurodegeneration of Dorsal and Ventral Hippocampal Dentate Gyrus: A Study with Transgenic Mice Overexpressing GSK3Î². PLoS ONE, 2011, 6, e27262.	2.5	33
79	Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. Human Molecular Genetics, 2015, 24, 5040-5052.	2.9	33
80	Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3Î²/PP1 imbalance. Human Molecular Genetics, 2013, 22, 466-482.	2.9	32
81	Bi-directional genetic modulation of GSK-3Î² exacerbates hippocampal neuropathology in experimental status epilepticus. Cell Death and Disease, 2018, 9, 969.	6.3	32
82	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. PLoS ONE, 2019, 14, e0210864.	2.5	31
83	Phospho-Tau Changes in the Human CA1 During Alzheimerâ€™s Disease Progression. Journal of Alzheimer's Disease, 2019, 69, 277-288.	2.6	29
84	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Molecular and Cellular Biochemistry, 2005, 278, 203-212.	3.1	28
85	Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 97-101.	1.4	27
86	Sources of Extracellular Tau and its Signaling. Journal of Alzheimer's Disease, 2014, 40, S7-S15.	2.6	27
87	MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus. Frontiers in Molecular Neuroscience, 2018, 11, 442.	2.9	26
88	Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochemical Society Transactions, 2010, 38, 977-980.	3.4	24
89	Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. Expert Opinion on Therapeutic Targets, 2016, 20, 653-661.	3.4	24
90	A Simple Model to Study Tau Pathology. Journal of Experimental Neuroscience, 2016, 10, JEN.S25100.	2.3	23

#	Article	IF	Citations
91	GSK3Î² Overexpression in Dentate Gyrus Neural Precursor Cells Expands the Progenitor Pool and Enhances Memory Skills. Journal of Biological Chemistry, 2016, 291, 8199-8213.	3.4	23
92	Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochimica Et Biophysica Acta - General Subjects, 2005, 1721, 16-26.	2.4	22
93	The role of the VQIVYK peptide in tau protein phosphorylation. Journal of Neurochemistry, 2007, 103, 1447-1460.	3.9	22
94	Differences in structure and function between human and murine tau. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2024-2030.	3.8	22
95	Identification of nitric oxide synthases in isolated bovine brain vessels. Neuroscience Research, 1996, 25, 195-199.	1.9	21
96	Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. Brain Research, 2002, 935, 65-72.	2.2	21
97	In vitro tau fibrillization: Mapping protein regions. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 683-692.	3.8	21
98	Secretion of full-length tau or tau fragments in a cell culture model. Neuroscience Letters, 2016, 634, 63-69.	2.1	21
99	Decreased adult neurogenesis in hibernating Syrian hamster. Neuroscience, 2016, 333, 181-192.	2.3	21
100	Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1. Nature Communications, 2017, 8, 2275.	12.8	21
101	The Involvement of Cholinergic Neurons in the Spreading of Tau Pathology. Frontiers in Neurology, 2013, 4, 74.	2.4	20
102	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 159-177.	7.7	20
103	Tau Aggregation. Neuroscience, 2023, 518, 64-69.	2.3	20
104	Changes in tau phosphorylation in hibernating rodents. Journal of Neuroscience Research, 2013, 91, 954-962.	2.9	19
105	Induction of Paclitaxel Resistance by the Kaposi's Sarcoma-Associated Herpesvirus Latent Protein LANA2. Journal of Virology, 2008, 82, 1518-1525.	3.4	18
106	Calpainâ€mediated truncation of GSKâ€3 in postâ€mortem brain samples. Journal of Neuroscience Research, 2009, 87, 1156-1161.	2.9	18
107	Memantine Inhibits Calpain-Mediated Truncation of GSK-3 Induced by NMDA: Implications in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 843-848.	2.6	18
108	Frontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment. Frontiers in Cellular Neuroscience, 2018, 12, 202.	3.7	18

#	Article	IF	Citations
109	<i>ACE2</i> is on the X chromosome: could this explain COVID-19 gender differences?. European Heart Journal, 2020, 41, 3095-3095.	2.2	18
110	Microtubule Depolymerization and Tau Phosphorylation. Journal of Alzheimer's Disease, 2013, 37, 507-513.	2.6	17
111	Tauâ€positive nuclear indentations in P301S tauopathy mice. Brain Pathology, 2017, 27, 314-322.	4.1	17
112	Adenosine receptorâ€induced second messenger production in adult guineaâ€pig cerebellum. British Journal of Pharmacology, 1993, 110, 1085-1090.	5.4	16
113	Tau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders. Current Aging Science, 2008, 1, 56-61.	1.2	16
114	Looking for novel functions of tau. Biochemical Society Transactions, 2012, 40, 653-655.	3.4	16
115	Forskolin and 3â€Isobutylâ€1â€Methylxanthine Increase Basal and Sodium Nitroprussideâ€Elevated Cyclic GMP Levels in Adult Guineaâ€Pig Cerebellar Slices. Journal of Neurochemistry, 1994, 62, 2212-2218.	3.9	15
116	Mass spectrometric identification and structural analysis of the third-generation synthetic cannabinoids on the UK market since the 2013 legislative ban. Forensic Toxicology, 2017, 35, 376-388.	2.4	15
117	Argyrophilic Grain Pathology as a Natural Model of Tau Propagation. Journal of Alzheimer's Disease, 2014, 40, S123-S133.	2.6	14
118	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. Biomolecular Concepts, 2018, 9, 1-11.	2.2	14
119	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntingtonâ€™s disease. Science Translational Medicine, 2021, 13, eabe7104.	12.4	14
120	Dual mechanism of phosphatidylinositol hydrolysis by substance P in brain. FEBS Journal, 1988, 172, 547-552.	0.2	13
121	Coenzyme Q Induces Tau Aggregation, Tau Filaments, and Hirano Bodies. Journal of Neuropathology and Experimental Neurology, 2008, 67, 428-434.	1.7	13
122	Calpain regulates N-terminal interaction of GSK-3Î² with 14-3-3Î¶, p53 and PKB but not with axin. Neurochemistry International, 2011, 59, 97-100.	3.8	13
123	Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice. Neuroscience, 2011, 196, 215-227.	2.3	13
124	The Expression and Localisation of G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels Is Differentially Altered in the Hippocampus of Two Mouse Models of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11106.	4.1	13
125	Nuclear localization of Î²-catenin in adult mouse thalamus correlates with low levels of GSK-3Î². NeuroReport, 1999, 10, 2699-2703.	1.2	12
126	Focal cerebral ischemia induces changes in oligodendrocytic tau isoforms in the damaged area. Glia, 2020, 68, 2471-2485.	4.9	12

#	Article	IF	Citations
127	Molecular forms of butyrylcholinesterase in rat brain microvessels. Neuroscience Letters, 1990, 120, 46-49.	2.1	11
128	Intra and Extracellular Protein Interactions with Tau. Current Alzheimer Research, 2010, 7, 670-676.	1.4	11
129	Transgenic Mouse Models with Tau Pathology to Test Therapeutic Agents for Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 51-58.	2.4	10
130	TNAP Plays a Key Role in Neural Differentiation as well as in Neurodegenerative Disorders. Sub-Cellular Biochemistry, 2015, 76, 375-385.	2.4	10
131	Microtubule-associated protein tau in murine kidney: role in podocyte architecture. Cellular and Molecular Life Sciences, 2022, 79, 97.	5.4	10
132	Endothelin Stimulates Protein Phosphorylation in Bloodâ€“Brain Barrier. Biochemical and Biophysical Research Communications, 1996, 219, 366-369.	2.1	9
133	Glycogen synthase kinase-3Î² regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2017, 74, 1153-1163.	5.4	9
134	Peripheral nervous system effects in the PS19 tau transgenic mouse model of tauopathy. Neuroscience Letters, 2019, 698, 204-208.	2.1	9
135	Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3Î². Neuroscience, 2008, 157, 772-780.	2.3	8
136	Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model. Journal of Alzheimer's Disease, 2017, 60, 651-661.	2.6	8
137	Overexpression of GSK-3Î² in Adult Tet-OFF GSK-3Î² Transgenic Mice, and Not During Embryonic or Postnatal Development, Induces Tau Phosphorylation, Neurodegeneration and Learning Deficits. Frontiers in Molecular Neuroscience, 2020, 13, 561470.	2.9	8
138	Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins. Vaccines, 2020, 8, 127.	4.4	8
139	Tau and neuron aging. , 2013, 4, 23-8.		8
140	Natriuretic peptideâ€induced cyclic GMP accumulation in adult guineaâ€pig cerebellar slices. British Journal of Pharmacology, 1994, 113, 216-220.	5.4	7
141	A mouse model to study tau pathology related with tau phosphorylation and assembly. Journal of the Neurological Sciences, 2007, 257, 250-254.	0.6	7
142	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience, 2015, 9, 145.	2.8	7
143	Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2017, 56, 977-990.	2.6	7
144	Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. Brain Research Bulletin, 2007, 72, 121-123.	3.0	6

#	Article	IF	Citations
145	Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3Î²-overexpressing mice. Molecular Psychiatry, 2013, 18, 395-395.	7.9	6
146	New Beginnings in Alzheimerâ€™s Disease: The Most Prevalent Tauopathy. Journal of Alzheimer's Disease, 2018, 64, S529-S534.	2.6	6
147	Tau Protein as a New Regulator of Cellular Prion Protein Transcription. Molecular Neurobiology, 2020, 57, 4170-4186.	4.0	6
148	p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function. Molecular Neurobiology, 2022, 59, 1632-1648.	4.0	6
149	Characterization of Alzheimer paired helical filaments by electron microscopy. Microscopy Research and Technique, 2005, 67, 121-125.	2.2	5
150	Tau Kinase I Overexpression Induces Dentate Gyrus Degeneration. Neurodegenerative Diseases, 2010, 7, 13-15.	1.4	5
151	GSK3Î² overexpression driven by GFAP promoter improves rotarod performance. Brain Research, 2019, 1712, 47-54.	2.2	5
152	p38 activation occurs mainly in microglia in the P301S Tauopathy mouse model. Scientific Reports, 2022, 12, 2130.	3.3	5
153	Temperature effects on cholinesterases from rat brain capillaries. Bioscience Reports, 1986, 6, 573-577.	2.4	4
154	Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. Thrombosis Research, 1994, 75, 121-132.	1.7	4
155	Further studies on the mechanism of action of substance P in rat brain, involving selective phosphatidylinositol hydrolysis. Neurochemical Research, 1995, 20, 1147-1153.	3.3	4
156	Involvement of calcium in phosphoinositide metabolism in the blood-brain barrier. Cellular Signalling, 1995, 7, 261-267.	3.6	4
157	Endothelin-1 stimulates myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation in rat cerebellar slices. Neuroscience Letters, 1995, 194, 53-56.	2.1	4
158	Endothelin Inhibits Histamine-Induced Cyclic AMP Accumulation in Bovine Brain Vessels. Microvascular Research, 2000, 60, 49-54.	2.5	4
159	Endothelin-1 increases isoprenaline-enhanced cyclic AMP levels in cerebral cortex. Regulatory Peptides, 2000, 88, 41-46.	1.9	4
160	Specific Profile of Tau Isoforms in Argyrophylic Grain Disease. Journal of Experimental Neuroscience, 2013, 7, JEN.S12202.	2.3	4
161	Commentary: Genome-wide association study identifies 74 loci associated with educational attainment. Frontiers in Molecular Neuroscience, 2017, 10, 23.	2.9	4
162	Protein Biomarkers for the Diagnosis of Alzheimerâ€™s Disease at Different Stages of Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 6749.	4.1	4

#	Article	IF	Citations
163	Tetrahydroaminoacridine affects the cholinergic function of blood-brain barrier. Life Sciences, 1993, 53, 1165-1172.	4.3	3
164	Nitric Oxide Mediates the PAF-Stimulated Cyclic GMP Production in Hippocampal Slices. Biochemical and Biophysical Research Communications, 1996, 226, 27-31.	2.1	3
165	Regulation of phosphoinositide cycle by intracellular sodium in the blood-brain barrier. Cellular Signalling, 1996, 8, 387-392.	3.6	3
166	Heterogeneity of Î²-Adrenoceptors in Guinea-Pig Brain: Radioligand Binding and Cyclic Nucleotide Generation. Journal of Neurochemistry, 2002, 68, 2610-2617.	3.9	3
167	Neuronal Models for Studying Tau Pathology. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	2.0	3
168	Excitotoxicity induced by kainic acid provokes glycogen synthase kinase-3 truncation in the hippocampus. Brain Research, 2015, 1611, 84-92.	2.2	3
169	Glycolysis and gluconeogenesis: A teaching view. Journal of Biological Chemistry, 2021, 296, 100016.	3.4	3
170	Protein phosphorylation in the blood-brain barrier. Possible presence of marcks in brain microvessels. Neurochemistry International, 1996, 28, 59-65.	3.8	2
171	Endothelin enhances adenosine and isoprenaline elevated cyclic AMP levels in rat cerebellar slices. Peptides, 1999, 20, 1115-1122.	2.4	2
172	Binding of Tau Protein to the Ends of ex vivo Paired Helical Filaments. Journal of Alzheimer's Disease, 2008, 13, 177-185.	2.6	2
173	Tau Phosphorylation. Advances in Neurobiology, 2011, , 73-82.	1.8	2
174	Tau Triggers Tear Secretion by Interacting with Muscarinic Acetylcholine Receptors in New Zealand White Rabbits. Journal of Alzheimer's Disease, 2014, 40, S71-S77.	2.6	2
175	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. International Journal of Physiology, Pathophysiology and Pharmacology, 2018, 10, 172-183.	0.8	2
176	TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy. Neurobiology of Disease, 2022, 165, 105632.	4.4	2
177	Specific Peptide from the Novel W-Tau Isoform Inhibits Tau and Amyloid Î² Peptide Aggregation <i>In Vitro</i>. ACS Chemical Neuroscience, 0, , .	3.5	2
178	Human Brain Single Nucleotide Polymorphism: Validation of DNA Sequencing. Journal of Alzheimer's Disease Reports, 2018, 2, 103-109.	2.2	1
179	Role of Polyglycine Repeats in the Regulation of Glycogen Synthase Kinase Activity. Protein and Peptide Letters, 2008, 15, 586-589.	0.9	1
180	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease. , 0, , 601-607.		0

#	Article	IF	Citations
181	O2-05-01 Different ways for tau assembly. Neurobiology of Aging, 2004, 25, S41.	3.1	0
182	GSK-3, a Key Player in Alzheimer's Disease. , 0, , 105-124.		0
183	Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies. , 0, , 203-219.		0
184	Centro de Biologia Molecular â€œSevero Ochoaâ€: A Center for Basic Research into Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 325-335.	2.6	0
185	B24 Huntington's Disease As A Tauopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A17-A17.	1.9	0
186	Boronate-Tau Mediated Uptake in Neurons. Journal of Alzheimer's Disease, 2014, 40, 143-151.	2.6	0
187	Co-expression of FTDP-17 Human Tau and GSK-3ÃŸ (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration. , 2008, , 337-342.		0